On September 17, 2026, BlackRock, Inc. acquired 10.94 million shares of CSPC Pharma (01093) by way of taking a security interest in shares via an off-exchange transaction (nature of consideration: non-cash assets).

Prior to the acquisition, BlackRock, Inc.'s long position in CSPC Pharma was 565.29 million shares, representing 4.91%; following the acquisition, the holding changed to 576.23 million shares, with the long position ratio rising to 5.0%.